Henk Visscher1, S Rod Rassekh2, George S Sandor3, Huib N Caron4, Elvira C van Dalen4, Leontien C Kremer4, Helena J van der Pal4,5, Paul C Rogers2, Michael J Rieder6, Bruce C Carleton7, Michael R Hayden1, Colin J Ross1,7. 1. Centre for Molecular Medicine & Therapeutics, Child & Family Research Institute, Department of Medical Genetics, University of British Columbia, 950 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada. 2. Division of Pediatric Hematology/Oncology/BMT, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. 3. Division of Pediatric Cardiology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. 4. Department of Pediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands. 5. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Paediatrics, Children's Hospital/London Health Sciences Centre, London, ON, Canada. 7. Division of Translational Therapeutics, Department of Pediatrics, Child & Family Research Institute, University of British Columbia, Vancouver, BC, Canada.
Abstract
AIM: To identify novel variants associated with anthracycline-induced cardiotoxicity and to assess these in a genotype-guided risk prediction model. PATIENTS & METHODS: Two cohorts treated for childhood cancer (n = 344 and 218, respectively) were genotyped for 4578 SNPs in drug ADME and toxicity genes. RESULTS: Significant associations were identified in SLC22A17 (rs4982753; p = 0.0078) and SLC22A7 (rs4149178; p = 0.0034), with replication in the second cohort (p = 0.0071 and 0.047, respectively). Additional evidence was found for SULT2B1 and several genes related to oxidative stress. Adding the SLC22 variants to the prediction model improved its discriminative ability (AUC 0.78 vs 0.75 [p = 0.029]). CONCLUSION: Two novel variants in SLC22A17 and SLC22A7 were significantly associated with anthracycline-induced cardiotoxicity and improved a genotype-guided risk prediction model, which could improve patient risk stratification.
AIM: To identify novel variants associated with anthracycline-induced cardiotoxicity and to assess these in a genotype-guided risk prediction model. PATIENTS & METHODS: Two cohorts treated for childhood cancer (n = 344 and 218, respectively) were genotyped for 4578 SNPs in drug ADME and toxicity genes. RESULTS: Significant associations were identified in SLC22A17 (rs4982753; p = 0.0078) and SLC22A7 (rs4149178; p = 0.0034), with replication in the second cohort (p = 0.0071 and 0.047, respectively). Additional evidence was found for SULT2B1 and several genes related to oxidative stress. Adding the SLC22 variants to the prediction model improved its discriminative ability (AUC 0.78 vs 0.75 [p = 0.029]). CONCLUSION: Two novel variants in SLC22A17 and SLC22A7 were significantly associated with anthracycline-induced cardiotoxicity and improved a genotype-guided risk prediction model, which could improve patient risk stratification.
Entities:
Keywords:
anthracyclines; association study; cardiotoxicity; childhood cancer; pharmacogenomics
Authors: Marelize Swart; Wesley M Stansberry; Victoria M Pratt; Elizabeth B Medeiros; Patrick J Kiel; Fei Shen; Bryan P Schneider; Todd C Skaar Journal: J Mol Diagn Date: 2019-02-20 Impact factor: 5.568
Authors: Bryan P Schneider; Fei Shen; Laura Gardner; Milan Radovich; Lang Li; Kathy D Miller; Guanglong Jiang; Dongbing Lai; Anne O'Neill; Joseph A Sparano; Nancy E Davidson; David Cameron; Irmina Gradus-Pizlo; Ronald A Mastouri; Thomas M Suter; Tatiana Foroud; George W Sledge Journal: Clin Cancer Res Date: 2016-12-19 Impact factor: 12.531
Authors: Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton Journal: Br J Clin Pharmacol Date: 2016-06-30 Impact factor: 4.335
Authors: Eric J Chow; Kirsten K Ness; Gregory T Armstrong; Nickhill Bhakta; Jennifer M Yeh; Smita Bhatia; Wendy Landier; Louis S Constine; Melissa M Hudson; Paul C Nathan Journal: Semin Oncol Date: 2020-03-04 Impact factor: 4.929
Authors: Daniel L Hertz; Megan V Caram; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Nicholas J Seewald; Jeffrey Smerage; Melvyn Rubenfire; N Lynn Henry; Kathleen A Cooney; Monika Leja; Jennifer J Griggs; James M Rae Journal: Pharmacogenomics Date: 2016-01-22 Impact factor: 2.533